The trial participants will have been constrained during the trial to opt for alternative treatments.
With the conclusion of the Anavax trial, that constraint should be lifted, and the trial participants should be able to have access to NEU's Trofinetide, with its demonstrable patient benefits.
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-99
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.68 |
Change
-0.100(0.48%) |
Mkt cap ! $2.643B | |||
| Open | High | Low | Value | Volume |
| $20.50 | $20.74 | $20.01 | $5.091M | 247.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 156 | $20.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.68 | 256 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |